Fresenius Kabi receives FDA approval of three-chamber bag for parenteral nutrition

Fresnius Kabi's parenteral nutrition products--Courtesy of Fresenius Kabi

Fresenius Kabi announced on Aug. 26 that it has received FDA approval of the Kabiven and Perikabiven parenteral nutrition products in a three-chamber bag.

"We are pleased to bring new alternatives like Kabiven and Perikabiven to U.S. patients. This is especially important as many of the macro- and micro-nutrients in Kabiven and Perikabiven have been in short supply in the United States," Fresenius Kabi USA CEO John Ducker said in a statement.

The company says the container is one-of-a-kind in the U.S. The bag contains intravenously infused solutions of lipids, dextrose, amino acids and electrolyte to provide patients with nutrition. In addition, the bag's contents remain shelf-stable until prepared for patient use, according to the release.

"The clinical nutrition and pharmacy communities are paying increased attention to improving the safety of parenteral nutrition infusion. Premixed parenteral nutrition solutions such as Kabiven and Perikabiven can be an integral part in standardizing this therapy and can help support PN safety," said Dr. Darlene Kelly, of the Oley Foundation for Home Parenteral and Enteral Nutrition, in a statement. "Furthermore, for people who require long-term parenteral nutrition at home, Kabiven and Perikabiven are particularly beneficial because they provide needed nutrition, including lipids, and don't require refrigeration, making travel more convenient."

Kabiven is sold in 85 countries and has already been used to treat 9 million patients since 1999.

- read the release

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…